Sirona Biochem Announces Patent for Anti-Aging Family of Compounds

VANCOUVER, BC--(Marketwired - April 01, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that a new patent application has been deposited by its subsidiary TFChem for a second generation of glycoprotein compounds. The first target marketplace for this technology will be anti-aging cosmetics. Future applications may include consumer packaged goods and prescription pharmaceuticals.

The Anti-Aging Project:

In the late 1960s Professor Arthur DeVries discovered that Antarctic fish were able to survive sub-zero temperatures under the polar icecaps thanks to glycoproteins that protect their cells.

Sirona and its subsidiary TFChem have successfully synthesized compounds derived from these naturally occurring glycoproteins and created an anti-aging technology intended to protect people's skin not just from cold temperatures but UV damage, oxidative stress and other catalysts of visible aging.

This project is also being championed by Jacques Cousteau's son and grandson, Jean-Michel and Fabien Cousteau, who will lend their names and global brand to support the commercialization of this new anti-aging cosmetic technology.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.